



Michelle Lujan Grisham
Governor

Patrick M. Allen
Cabinet Secretary

September 1, 2024

Below is the FY25 Estimate of the cost of purchasing vaccine for privately insured children in New Mexico, as required by the Vaccine Purchasing Act, NMAC 7.5.4.8 section G. This is the estimate of the total cost for procuring vaccines by the New Mexico Department of Health plus a 10% reserve. These vaccines are distributed to all participating Vaccines for Children providers at no cost to providers or families. The estimate will be used to invoice insurers and health plans on a quarterly basis starting September 1, 2024.

The estimate is based upon October 2023 – May 2024 actual vaccine orders for insured children (non-Vaccines for Children eligible) under age 19, then annualized taking into account seasonal variations from prior years. Questions may be sent to vpa.fund@doh.nm.gov.

Vaccine Presentation	FY 25 Doses Final Estimate	FY2025 Cost/dose (\$) as of 8/23/24	FY2025 Dose Final Estimate
ACTHIB	3,040	12.920	\$ 39,276.80
BOOSTRIX	7,270	47.392	\$ 344,539.84
BEXSERO	4,140	223.746	\$ 926,308.44
ENGERIX B	3,930	28.422	\$ 111,698.46
GARDASIL 9	11,070	287.535	\$ 3,183,012.45
HAVRIX	10,370	38.009	\$ 394,153.33
INFANRIX	4,980	28.795	\$ 143,399.10
IPOL	1,680	42.638	\$ 71,631.84
KINRIX	5,350	61.079	\$ 326,772.65
MENVEO	2,880	157.351	\$ 453,170.88
M-M-R II	4,520	92.494	\$ 418,072.88
PEDIARIX	5,130	97.967	\$ 502,570.71
PEDVAXHIB	5,670	29.709	\$ 168,450.03
PENTACEL	4,210	114.524	\$ 482,146.04
PREVNAR 20	15,770	261.560	\$ 4,124,801.20
PROQUAD (frozen, direct-ship)	6,130	270.148	\$ 1,656,007.24
RECOMBIVAX HB	470	27.116	\$ 12,744.52
ROTARIX	1,870	138.741	\$ 259,445.67
ROTATEQ	10,990	95.962	\$ 1,054,622.38
TENIVAC	100	37.102	\$ 3,710.20
TRUMENBA	530	190.260	\$ 100,837.80
VAQTA	2,280	37.735	\$ 86,035.80
VARIVAX (frozen, direct-ship)	3,590	174.323	\$ 625,819.57
Menquadfi	10,640	166.984	\$ 1,776,709.76
Vaxelis	6,780	150.850	\$ 1,022,763.00
Vaxneuvance	9,270	222.546	\$ 2,063,001.42
Jynneos	100	270.000	\$ 27,000.00
Beyfortus	2,000	519.750	\$ 1,039,500.00
Abrysvo	400	295.000	\$ 118,000.00
Penbraya	400	230.750	\$ 92,300.00
Moderna COVID (12 yrs+)	1,180	141.800	\$ 167,324.00
Moderna COVID (6mo.-11yrs)	2,110	129.000	\$ 272,190.00
Pfizer COVID (12 yrs+)	1,500	136.750	\$ 205,125.00
Pfizer COVID-19 Vaccine (5yrs-11yrs)	1,500	77.000	\$ 115,500.00
Pfizer COVID-19 Vaccine (6mo.-4yrs)	1,500	57.500	\$ 86,250.00
Subtotal (non flu)			\$ 22,474,891.01
Total Influenza			\$ 428,790.00
Cost - all doses			\$ 22,903,681.01
10% Reserve			\$ 2,290,368.10
Total			\$ 25,194,049.11

Flu Order	Fluzone - Quad 6 months+ 10,000 Doses
	FluLaval - Quad 6 months+ 10,000 Doses
	FluMist Quad 2yrs+ 1,000 Doses

The FY25 estimate is \$25,194,049.11

The calculation is the following:

The formula reflects the surplus that exceeds the 10% Reserve carried from FY24

$\$20,383,373.00 \text{ Total} \div 138,571 \text{ Lives} = \$147.09 \text{ Annual Cost Per-Life}$

$\$147.09 \text{ Annual Cost} \div 4 \text{ Quarters} = \$36.77 \text{ Unit Cost Per Life Each Billing Quarter}$